CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 500 target
Drug / intervention
EXELIONother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07224724
NCT07224724N/ARecruitingOn TrackUpdated 5mo ago

Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases

City of Hope Medical Center·observational·Posted Nov 5, 2025·Updated Jan 28, 2026

In Brief

An observational study evaluating EXELION for Colorectal Cancer Liver Metastases (CRLM) and Metastatic Colorectal Carcinoma (mCRC). Currently recruiting, targeting 500 participants across 1 site.

Detailed Summary

Colorectal cancer is the third most common malignancy worldwide, and prognosis largely depends on how effectively metastatic disease is managed. The liver is the most frequent and prognostically important site of metastasis, and patients responding well to chemotherapy may become candidates for curative hepatic resection. However, the presence of extrahepatic metastasis (EHM) critically influences treatment eligibility and survival. Although clinical scores such as the Fong and Beppu systems include EHM as a determinant, its detection by imaging remains limited, especially for small or occult lesions. Accurate identification of EHM is also essential when considering liver transplantation for unresectable colorectal liver metastases (CRLM), where EHM remains an exclusion criterion. The EXELION Study aims to develop a non-invasive diagnostic model using serum exosomal microRNAs (miRNAs) to detect both hepatic and extrahepatic metastases in patients with CRLM. By integrating circulating miRNA profiling with machine learning-based analysis, this study seeks to supplement imaging diagnostics, improve treatment stratification, and enhance clinical decision-making for metastatic colorectal cancer.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ARecruitingOverdue
20252026
First PostedNov 5, 2025
Enrollment StartJun 1, 2024
Primary CompletionJun 18, 2026
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 8 months ago

Interventions

EXELIONother

A panel of exosomal microRNA, whose expression level is tested in serum or plasma